Company intelligence / Profile preview

NovoStent

Mountain View, California, United Statesrivm.nl ↗

Ownership: Private
Development stage: Other

Overview

As of 2008–2010, NovoStent had completed enrollment in a European clinical trial evaluating its peripheral stents for the treatment of superficial femoral and popliteal artery disease. The company announced successful implantation of what was then the world’s longest peripheral stents (250 mm) as part of this study. No recent clinical results are available.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Montreux Equity Partners (investor/partner)

Beyond the preview

Go deeper on NovoStent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoStent.

Explore the full profile